Axsome Therapeutics To Report Fourth Quarter And Full Year 2024 Financial Results On February 18 By Investing.com

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) — Axome Therapeutics, Inc. (NASDAQ: NASDAQ: ) a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, announced today that it will report Financial results for the fourth quarter and full year of 2024 are due Tuesday, February 18, 2025, before the US financial close. Markets. Axome’s management will host a conference call at 8:00 am Eastern Time to discuss these results and provide a business update.

To participate in the live conference call, please dial (877) 405-1239 (toll free domestic) or +1 (201) 389-0851 (international). The conference call can be accessed live on the Webcasts and Presentations page of the Investors section of the website at www.axsome.com. A replay of the conference call will be available on the company’s website for 30 days following the live event.

About Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific findings by identifying critical gaps in care and develop differentiated products with a focus on innovative approaches that drive meaningful improvements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder and excessive daytime sleepiness associated with narcolepsy and sleep apnea, as well as a variety of intensive neurological and psychiatric programs impacting more than 150 million people. United States. We’re together to solve some of the brain’s biggest problems so patients and their loved ones can thrive.

Forward-looking statements

Certain matters discussed in this press release are forward-looking statements. The Company may, in certain circumstances, use words such as predict, believe, potential, may, continue, estimate, estimate, expect, plan, consider, may, could, be, should or other words that describe uncertainty of future events or results. To identify these forward-looking statements. In particular, the company’s statements regarding trends and possible future results are examples of such forward-looking statements. Forward-looking statements involve risks and uncertainties, including the continued commercial success of the Company’s Sunosi ® and Auvelity ® products and the success of the Company’s efforts to develop additional indications for solriamfetol. / or AXS-05; the company’s ability to maintain and expand payer coverage; The success, timing and cost of the Company’s ongoing clinical trials and the expected clinical trials for the Company’s current product candidates, including the timing of initiation, enrollment speed and trial completion statements (including the Company’s stated ability to fully fund the Company) and any impact on the Company’s currently projected revenues or expenses. clinical trials that are not subject to change) futility analyzes and interim results received, final results of the Company’s ongoing clinical trials and/or data readings, and any New Drug Application (NDA); They are not indicative of the number or type or nature of studies required to support enrollment. ACCORD and ADVANCE clinical trials, including statements regarding the Company’s ability to file an NDA for Alzheimer’s disease activation, the Company’s current product candidates, the Company’s ability to fund additional clinical trials to continue the development of the Company’s product candidates, the Company’s US Food and Drug Administration (FDA) or other regulatory authority approval or other including statements regarding the timing of the Company’s ability to acquire and retain product candidates and the Company’s ability to submit any NDA. The issues identified by the FDA in the full response letter include the company’s NDA for AXS-07 in the acute treatment of migraine in adults with or without aura, the company’s unique protocol review for the MOMENTUM clinical trial, the company’s ability to successfully protect its intellectual property or obtain necessary licenses at a cost acceptable to the company. , no matter what; Successful implementation of the company’s research and development programs and collaborations; the success of the Company’s license agreements; market acceptance of the Company’s products and product candidates if approved; the Company’s expected capital requirements, including the amount of capital required to commercialize Sunosi and Avelty and the Company’s other product candidates, if approved, and the impact on the Company’s expected cash flow, the Company’s ability to convert sales into recognized revenue and gross revenue into net sales; Unforeseen circumstances or related to the domestic political climate, geo-political conflicts or global pandemics or conditions outside the Company’s control, including disruptions to the Company’s normal business operations and other general economic conditions and regulatory developments. The factors discussed herein could cause actual results and developments to differ materially from those expressed or implied in such statements. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investors:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com

Media:
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com